Sign In
Buy MYOV
$26.98
+0 (+0%)
At Close: Jun 08, 2023
Myovant Sciences: What The Sumitomo Offer Foretells
06:44pm, Friday, 07'th Oct 2022
As Myovant overcame the odds as I forecast, Myfembree garnered another FDA approval to treat endometriosis. Subsequent to the said game-changing event, Sumitomo made an offer to acquire all outstandin
Myovant: Sumitomo Bid Is A Head Scratcher, Where Is The Value?
02:34pm, Tuesday, 04'th Oct 2022
Myovant stock has rocketed in value by >100% since my last (bearish) note on the company. The main reason for the Myovant gains is an attempt by majority shareholder Sumitomo to acquire remaining shar
Why Myovant Sciences Stock Is Skyrocketing Today
11:49am, Monday, 03'rd Oct 2022
Myovant said "no thanks" to an acquisition offer in hopes to fetch a higher price.
Myovant stock opened 35% up on Monday: here's the catalyst
11:24am, Monday, 03'rd Oct 2022
Myovant Sciences Ltd (NYSE: MYOV) opened nearly 35% up on Monday after the biopharmaceutical company said it rejected a buyout proposal from its largest shareholder. Myovant is open to considering a b
Myovant Sciences Stock Skyrockets After Rejecting Buyout Offer
10:24am, Monday, 03'rd Oct 2022
Myovant Sciences Ltd (NYSE:MYOV) stock is soaring today, up 35.7% at $24.48 at last glance, after the biopharmaceutical name rejected a buyout offer from Japan-based Sumitomo Pharma.
Why Is Myovant Sciences (MYOV) Stock Up 30% Today?
10:10am, Monday, 03'rd Oct 2022
Myovant Sciences (NYSE: MYOV ) stock is skyrocketing over 30% today on news that the British biopharmaceutical company has received a buyout offer. MYOV stock surged as much as 31% in premarket tradin
Myovant Sciences Rockets After Rejecting Lowball Sumitovant Biopharma Takeover Bid
10:02am, Monday, 03'rd Oct 2022
Myovant Sciences turned down a takeover bid from majority shareholder Sumitovant Biopharma on Monday, and MYOV stock skyrocketed. The post Myovant Sciences Rockets After Rejecting Lowball Sumitovant B
Myovant stock soars after confirming buyout bid, but said it 'significantly undervalues' the company
06:42am, Monday, 03'rd Oct 2022
Shares of Myovant Sciences Ltd. MYOV, +2.34% shot up 27.2% in premarket trading Monday toward an 11-month high, after the biopharmaceutical company confirmed over the weekend that it received an unsol
Women Can Thank Pfizer And Myovant For MYFEMBREE
10:49am, Tuesday, 20'th Sep 2022
The compelling results of endometriosis treatment MYFEMBREE's phase 3 led to the drug's approval, and Myovant will be eligible for up to $200 million based on achieving certain milestones. The endomet
Myovant Sciences to Participate at Upcoming Investor Conferences
06:45am, Friday, 02'nd Sep 2022
BASEL, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, e
Myovant Sciences: Regulatory Overhang Cleared
04:14pm, Monday, 29'th Aug 2022
Myovant secured FDA approval for Myfembree for the treatment of endometriosis in early August. The approval clears the regulatory overhang on the stock but now comes the harder part - commercializatio
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q1 2022 Results - Earnings Call Transcript
08:51pm, Wednesday, 27'th Jul 2022
Myovant Sciences Ltd. (NYSE:MYOV ) Q1 2022 Results Conference Call July 27, 2022 5:00 PM ET Company Participants Uneek Mehra - Chief Financial & Business Officer Dave Marek - Chief Executive Officer L
Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree
08:49am, Monday, 18'th Jul 2022
Myovant has performed well since the regulatory setback in April. The PDUFA date for the sNDA for Myfembree has been extended by three months and Orgovyx was approved in Europe.
Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022
06:45am, Wednesday, 13'th Jul 2022
BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for
Myovant Sciences (MYOV) Moves 7.7% Higher: Will This Strength Last?
09:20am, Monday, 20'th Jun 2022
Myovant Sciences (MYOV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more st
